Compare Ascendis Pharma A/S (ASND) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs KB Financial Group, Inc. — how do they compare? Ascendis Pharma A/S trades at $256.37 (market cap $16.67B), while KB Financial Group, Inc. trades at $117.85 (market cap $41.21B). The key difference: KB Financial Group, Inc. is far larger — about 2.5× Ascendis Pharma A/S's market cap, and KB Financial Group, Inc. pays a 2.67% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KB | |
|---|---|---|
Market Cap | $16.67B | $41.21B |
Sector | Health | Financials |
52-Week High | $277.18 | $124.01 |
52-Week Low | $189.74 | $77.50 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
KB Financial Group (KB) trades at $118.00, down 2.26% today, with a bullish technical signal from moving averages. The stock shows strong fundamental performance with consistent earnings beats, 27.82% net income margin, and attractive valuation at P/E of 10.36 and P/B of 0.98. Recent news highlights momentum potential and diversification into non-banking segments, which now contribute 43% of earnings.
Outlook remains positive with earnings growth and shareholder returns as key catalysts, though risks include volatile operating environment and heavy investing cash outflows. Analyst consensus leans cautious with 67% hold ratings, suggesting potential upside requires continued execution on diversification and fee income growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
